Evidence map›Paper›PMID 40180500›Full record

SynthesisThe American journal of clinical nutrition2025

High-dose docosahexaenoic acid for bronchopulmonary dysplasia severity in very preterm infants: a collaborative individual participant data meta-analysis.

Isabelle Marc, Pascal M Lavoie, Thomas R Sullivan, Etienne Pronovost, Amélie Boutin, Marc Beltempo, Mireille Guillot, Jacqueline F Gould, David Simonyan, Andrew J McPhee and 3 more

Registry-linked trialAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05915806 (Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05915806 naactive not recruitingnot on this map

Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants: A Collaborative Study Protocol for an Individual Participant Data Meta-analysis

TypeinterventionalSponsorCHU de Quebec-Universite LavalRan2023 to 2026Enrolled1,801ConditionsBronchopulmonary Dysplasia, Child Development, Neonatal and Perinatal ConditionsArmsHigh-dose DHA, Control
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Isabelle MarcDepartment of Pediatrics, CHU de Québec-Université Laval, Québec city, Quebec, Canada. Electronic address: isabelle.marc@crchudequebec.ulaval.ca.
Pascal M LavoieDepartment of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Thomas R SullivanWomen and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Public Health, University of Adelaide, Adelaide, South Australia, Australia.
Etienne PronovostDepartment of Pediatrics, CHU de Québec-Université Laval, Québec city, Quebec, Canada.
Amélie BoutinDepartment of Pediatrics, CHU de Québec-Université Laval, Québec city, Quebec, Canada.
Marc BeltempoDepartment of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montréal, Quebec, Canada.
Mireille GuillotDepartment of Pediatrics, CHU de Québec-Université Laval, Québec city, Quebec, Canada.
Jacqueline F GouldWomen and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Medicine, University of Adelaide, Adelaide, South Australia, Australia; School of Psychology, University of Adelaide, Adelaide, South Australia, Australia.
David SimonyanClinical and Evaluative Research Platform, Centre de recherche du CHU de Québec-Université Laval, Québec City, Quebec, Canada.
Andrew J McPheeWomen and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Ibrahim MohamedDepartment of Pediatrics, Université de Montréal, CHU Sainte-Justine, Montréal, Quebec, Canada.
Lynne MooreDepartment of Social and Preventive Medicine, Université Laval, Québec City, Quebec, Canada.
Maria MakridesWomen and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeonatal supplementation with high-dose docosahexaenoic acid (DHA) omega-3 may benefit neurodevelopment in very preterm infants, but concerns remain regarding a potential increased risk and severity of bronchopulmonary dysplasia (BPD). However, the interpretation of evidence on the effect of DHA on severe BPD is challenging because of the heterogeneity in the BPD definitions used across trials.

objectivesThis study aims to determine whether, compared with placebo, neonatal enteral supplementation with high-dose DHA, mimicking placental transfer, is associated with severe BPD in very preterm infants using an individual participant data meta-analysis of randomized controlled trials (RCTs).

methodsRCTs were eligible if recently conducted in infants born with gestational age (GA) <29 wk and compared enteral supplementation with high-dose DHA alone with a placebo. Using a harmonized data set, the primary outcome of severe BPD was defined as the need for "high-flow" nasal cannula >2 L/min, noninvasive positive airway pressure, or invasive mechanical ventilation at 36 wk postmenstrual age. Secondary outcomes (N = 15) included death, "death or severe BPD," ordinal BPD severity grade, and common neonatal morbidities. Associations between high-dose DHA and outcomes were estimated using a one-stage meta-analysis approach.

resultsTwo RCTs were identified in a systematic review (searched up to August 1, 2022; N = 2304) that met inclusion criteria (N = 1801; 904 DHA and 897 placebo; GA 26.7 ± 1.5 wk). Severe BPD in survivors occurred in 290/843 (34.4%) infants in the DHA group and 268/841 (31.9%) infants in the placebo group {relative risk [RR], 1.06 [95% confidence interval (CI): 0.93, 1.21]; P = 0.36}. DHA was not associated with "death or severe BPD" [RR, 1.05 (95% CI: 0.94, 1.17); P = 0.41], the ordinal severity grade [odds ratio for a more severe grade, 1.20 (95% CI: 0.998, 1.45); P = 0.053], or other neonatal outcomes. There was limited evidence of heterogeneity for BPD-related outcomes.

conclusionsNeonatal enteral supplementation with high-dose DHA was not significantly associated with severe BPD in very preterm infants. TRIAL REGISTRATION NUMBER: This study was registered at clinicaltrials.gov as NCT05915806, https://clinicaltrials.gov/study/NCT05915806. META-ANALYSIS REGISTRY NUMBER AND WEBSITE: PROSPERO, CRD42023431063, https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=431063.

Indexed as

Bronchopulmonary DysplasiaDietary SupplementsDocosahexaenoic AcidsHumansInfant, Extremely PrematureInfant, NewbornInfant, PrematureRandomized Controlled Trials as TopicSeverity of Illness IndexDocosahexaenoic Acidsbronchopulmonary dysplasiadocosahexaenoic acidindividual participant data meta-analysisinfant nutritionomega-3preterm infant

Identifiers

PMID40180500
PMCPMC12002185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.